The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of